Utility Analyses of AVITI Sequencing Chemistry

Area of Science:

• Genomics and Molecular Biology
• Next-Generation Sequencing Technologies

Background:

• Massively parallel sequencing has revolutionized biology, enabling advances in genome and transcriptome sequencing.
• High-throughput short-read sequencing faces challenges in accuracy, cost, and competitive options.

Purpose of the Study:

• To comparatively analyze Element Biosciences' AVITI and Illumina's sequencing platforms.
• To evaluate performance in DNA and RNA short-read, synthetic long-read, and targeted single-cell transcript sequencing.

Main Methods:

• Comparative analysis of matched DNA and RNA short-read assays.
• Evaluation of synthetic long-read sequencing for RNA and targeted single-cell transcripts.
• Utilized Element AVITI and Illumina NextSeq 550/NovaSeq 6000 chemistries.

Main Results:

• AVITI demonstrated significantly higher per-sequence quality scores for both DNA and RNA short-read applications.
• AVITI showed substantially lower experimentally determined error rates: 89.7% for PCR-free DNA and 32.5% for RNA quantification.
• Both platforms performed comparably for synthetic long-read sequencing, with AVITI showing marginally lower error rates and higher mutation detection.

Conclusions:

• Element Biosciences' AVITI platform shows potential as a competitive option for high-throughput short-read sequencing.
• AVITI offers improved accuracy and lower error rates compared to Illumina's NextSeq 550 for specific applications.